GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Vitrolife AB (STO:VITR):
Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - June 2014. The presentation will be held in English.
Time: Friday, July 11, 2014 at 10 a.m. CET.
Registration can preferably be done in advance under the following link:
or shortly before the conference starts on:
• Sweden dial in number: +46 (0)8 5052 0110
• UK dial in number: +44 (0)20 7162 0077
Conference name: Vitrolife, conference ID: 946172
Thomas Axelsson, CEO
Mikael Engblom, CFO
The press release for Vitrolife’s interim report will be released at 08.30 a.m. CET on Friday, July 11, 2014.
Before the conference call, slides will be available at the company web page, www.vitrolife.com/en/Corporate/.
A recorded version of the conference call will be available for seven days on number +46 (0)8 5052 0333 (Sweden) or +44 (0)20 7031 4064 (UK), access code 946172.
Gothenburg, July 2, 2014
VITROLIFE AB (publ)
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469), Small Cap.
This information was brought to you by Cision http://news.cision.com